SAN DIEGO, June 24, 2020 /PRNewswire/ -- Biocept, Inc.
(Nasdaq: BIOC), a leading commercial provider of molecular
technologies designed to provide physicians with clinically
actionable information to improve the outcomes of patients with
cancer, announces it has entered into a managed care provider
agreement with Medical Cost Containment Professionals, LLC
(MCCP) to process out-of-network claims for Biocept's Target
Selector™ liquid biopsy testing. MCCP is a reference-based
pricing insurance network that includes more than 150,000 providers
nationwide.
"MCCP has a reputation for paying out-of-network claims
correctly, in full and on time; and we are delighted to be working
with them," said Dede Goehler,
Biocept's Senior Director of Managed Care Strategies. "Under
this new relationship, out-of-network claims for our Target
Selector™ testing will be adjudicated by MCCP at pre-negotiated
pricing in a timely manner, helping to accelerate collections while
reducing the length of time receivables remain outstanding."
"This agreement effectively expands our managed care network of
covered lives at a time when the healthcare community increasingly
recognizes the importance of our liquid biopsy tests in helping
physicians to determine the optimal treatment for their patients
with cancer," said Michael Nall,
Biocept's President and CEO. "MCCP's network includes 47
million covered lives, with some members covered by multiple plans.
We are working to enter into additional similar partnerships
that help adjudicate out-of-network claims, as well as with managed
care plans for in-network coverage for their members."
About MCCP
Medical Cost Containment Professionals, LLC
was founded by Principal and CEO Daniel
Ayala to help lower the cost of healthcare throughout
America. MCCP has been successful in driving down the cost of
business for its clients. MCCP's unique business model allows
for negotiation of 80% of the claims it receives regardless of the
amount. More information is available at www.mccpppo.com.
About Biocept
Biocept, Inc. is a molecular diagnostics
company with commercialized assays for lung, breast, gastric,
colorectal and prostate cancers, and melanoma. The Company uses its
proprietary liquid biopsy technology to provide physicians with
clinically actionable information for treating and monitoring
patients diagnosed with cancer. The Company's patented Target
Selector™ liquid biopsy technology platform captures and analyzes
tumor-associated molecular markers in both circulating tumor cells
(CTCs) and in circulating tumor DNA (ctDNA). With thousands of
tests performed, the platform has demonstrated the ability to
identify cancer mutations and alterations to inform physicians
about a patient's disease and therapeutic options. Additionally,
Biocept is offering nationwide COVID-19 polymerase chain reaction
(PCR) testing to support public health efforts during this
unprecedented pandemic. For more information, please
visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This
release contains forward-looking statements that are based upon
current expectations or beliefs, as well as a number of assumptions
about future events. Although we believe that the expectations
reflected in the forward-looking statements and the assumptions
upon which they are based are reasonable, we can give no assurance
that such expectations and assumptions will prove to have been
correct. Forward-looking statements are generally identifiable by
the use of words like "may," "will," "should," "could," "expect,"
"anticipate," "estimate," "believe," "intend," or "project" or the
negative of these words or other variations on these words or
comparable terminology. To the extent that statements in this
release are not strictly historical, including without limitation
statements regarding the adjudication of testing by MCCP at
pre-negotiated pricing in a timely manner and the benefits thereof,
the ability of MCCP to negotiate 80% of the claims it receives
regardless of the amount, the ability of our platform to
identify cancer mutations and alterations, and the ability of
our technologies to provide physicians with clinically actionable
information for treating and monitoring patients diagnosed with
cancer, such statements are forward-looking, and are made pursuant
to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. You are cautioned not to put undue reliance on
these forward-looking statements, as these statements are subject
to numerous risk factors as set forth in our Securities and
Exchange Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. You are advised to review our
filings with the SEC, which can be accessed over the Internet at
the SEC's website located at www.sec.gov.
Investor Contact:
LHA Investor
Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-enters-into-agreement-with-reference-based-pricing-network-medical-cost-containment-professionals-llc-to-process-out-of-network-claims-301082246.html
SOURCE Biocept, Inc.